Article | June 27, 2022

How A CDMO Achieves Finished Product Lyophilization With Limited And Expensive API

By Bryan Braxton, Ph.D., Senior Director, Aseptic R&D, Pii

iStock-941351188-lab-cleanroom-sterile

Stability is an inherent challenge in the early stages of development for both solid and liquid pharmaceutical ingredients. Lyophilization may the answer needed to complete formulation development and advance your candidate to Phase I clinical trials.

Lyophilization, or freeze drying, is a process in which water is removed from a product after it is frozen and placed under a vacuum, allowing the ice to change directly from solid to vapor without passing through a liquid phase. The process consists of three separate, unique, and interdependent processes: freezing, primary drying (sublimation), and secondary drying (desorption). But lyophilization can be challenging, expensive, and time-consuming.

Agile, cost-effective lyophilization services can accelerate the development of complex drug candidates that present stability challenges. Partnering with an agile CDMO that recognizes these obstacles, and can still formulate a finished product with limited and expensive active supply, is critical.

In this article, explore lyophilization development in the lab, lyophilization cycle development and optimization, and agile scale up.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Pharmaceutics International